drugset / Trial / NCT03854994
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute lymphoblastic leukemia （B-ALL）.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2021-08-01
- Completion
- 2022-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KD-019 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |